Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol by Sydes, Matthew R et al.
Treatment options for hormone naïve prostate cancer 
Title: Adding abiraterone or docetaxel to long-term hormone therapy for prostate 
cancer: directly randomised data from the STAMPEDE multi-arm, multi-
stage platform protocol  
  
Running 
Head: 
Treatment options for hormone-naïve prostate cancer 
  
Version & 
Date: 
v2.01; 10-Feb-2018 
  
Tables & 
Figures: 
Figures=5 
Tables=4 
Supplemental Figures = 2 
Supplemental Tables = 1 
  
 
 Name Affiliation Email 
 Matthew R Sydes MRC Clinical Trials Unit at UCL, London, 
UK 
m.sydes@ucl.ac.uk 
 Melissa R Spears MRC Clinical Trials Unit at UCL, London, 
UK 
melissa.gannon@lshtm.ac.u
k 
 Malcolm D Mason University of Cardiff, Cardiff, UK MasonMD@Cardiff.ac.uk 
 Noel W Clarke Christie and Royal Salford Hospital, 
Manchester, UK 
noel.clarke@christie.nhs.uk 
 David P Dearnaley Institute of Cancer Research, Sutton, UK davidd@icr.ac.uk 
 Johann S de Bono Institute of Cancer Research, Sutton, UK johann.de-bono@icr.ac.uk 
 Gert Attard University College London g.attard@ucl.ac.uk 
 Simon Chowdhury Guy's & St Thomas NHS, Foundation 
Trust, London, UK 
Simon.Chowdhury@gstt.nhs.
uk 
 Bill Cross St James University Hospital, Leeds, UK WilliamCross@nhs.net 
 Silke Gillessen Division of Oncology and Hematology, 
Kantonsspital St. Gallen, St. Gallen;  
University of Bern, Switzerland; 
Swiss Group for Cancer Clinical 
Research (SAKK), Bern, Switzerland 
silke.gillessen@kssg.ch 
 Zaf Malik Clatterbridge Cancer Centre, Liverpool, 
UK 
Zafar.Malik@clatterbridgecc.
nhs.uk 
 Rob Jones Institute of Cancer Sciences, Beatson 
West of Scotland Cancer Centre, 
University of Glasgow, UK 
r.jones@beatson.gla.ac.uk 
 Chris Parker Royal Marsden Hospital, Sutton, UK chris.parker@icr.ac.uk 
© The Author 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any 
medium, provided the original work is properly cited. 
 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy072/4910513
by Cardiff University user
on 26 March 2018
Treatment options for hormone naïve prostate cancer 
v2.01; 10-Feb-2018 2/49 
 Name Affiliation Email 
 Alastair WS Ritchie MRC Clinical Trials Unit at UCL, London, 
UK 
awsritchie@hotmail.com 
 J Martin Russell Institute of Cancer Sciences, Beatson 
West of Scotland Cancer Centre, 
University of Glasgow, UK 
martin.russell@nhs.net 
 Robin Millman MRC Clinical Trials Unit at UCL, London, 
UK  
robin.millman@ntlworld.com 
 David Matheson Faculty of Education, Health and 
Wellbeing, University of 
Wolverhampton, UK  
djmatheson@icloud.com 
 Claire Amos MRC Clinical Trials Unit at UCL, London, 
UK 
c.amos@ucl.ac.uk 
 Clare Gilson MRC Clinical Trials Unit at UCL, London, 
UK 
c.gilson@ucl.ac.uk 
 Alison Birtle Rosemere Cancer Centre, Royal Preston 
Hospital, Preston 
alison.birtle@lthtr.nhs.uk 
 Susannah Brock Dorset Cancer Centre, Poole Hospital, 
Poole, UK 
Susannah.Brock@poole.nhs.
uk 
 Lisa Capaldi Worcestershire Acute Hospitals NHS 
Trust, Worcester, UK 
lcapaldi@nhs.net 
 Prabir Chakraborti Royal Derby Hospital, Derby UK prabir.chakraborti1@nhs.net 
 Ananya Choudhury Division of Cancer Sciences, University 
of Manchester, Manchester Academic 
Health Science Centre, Christie Hospital 
NHS Foundation Trust, Manchester, UK 
ananya.choudhury@christie.
nhs.uk 
 Linda Evans Sheffield Teaching Hospitals NHS 
Foundation Trust 
Linda.Evans@sth.nhs.uk 
 Daniel Ford City Hospital, Cancer Centre at Queen 
Elizabeth Hospital, Birmingham 
Daniel.Ford@uhb.nhs.uk 
 Joanna Gale Portsmouth Oncology Centre, Queen 
Alexandra Hospital, Portsmouth, UK 
joanna.gale@porthosp.nhs.u
k 
 Stephanie Gibbs Queen's Hospital, Romford, UK Stephanie.Gibbs@bhrhospita
ls.nhs.uk 
 Duncan Gilbert Sussex Cancer Centre, Royal Sussex 
County Hospital, Brighton , UK 
Duncan.Gilbert@bsuh.nhs.u
k 
 Robert Hughes Mount Vernon Group, Mount Vernon 
Hospital, Middlesex, UK 
robert.hughes@nhs.net; 
rjhughes@doctors.org.uk 
 Duncan McLaren Western General Hospital, Edinburgh, 
UK 
Duncan.McLaren@nhslothian
.scot.nhs.uk 
 Jason Lester Velindre Cancer Centre, Cardiff, UK jason.lester2@wales.nhs.uk 
 Ashok Nikapota Sussex Cancer Centre, Brighton, UK ashok.nikapota@nhs.net 
 Joe O’Sullivan Centre for Cancer Research and Cell 
Biology, Queens University Belfast, UK;  
Belfast City Hospital, Belfast, UK 
joe.osullivan@qub.ac.uk 
 Omi Parikh Lancashire Teaching Hospitals NHS 
Trust, Preston, UK  
omi.parikh@lthtr.nhs.uk 
 Clive Peedell Department of Oncology & 
Radiotherapy, South Tees NHS Trust, 
Middlesbrough, UK 
Clive.Peedell@stees.nhs.uk 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy072/4910513
by Cardiff University user
on 26 March 2018
Treatment options for hormone naïve prostate cancer 
v2.01; 10-Feb-2018 3/49 
 Name Affiliation Email 
 Andrew Protheroe Oxford University Hospitals NHS 
Foundation Trust, UK 
Andrew.Protheroe@ouh.nhs.
uk 
 Sarah M Rudman Guy's & St Thomas NHS, Foundation 
Trust, London, UK 
sarah.rudman@gstt.nhs.uk 
 Richard Shaffer Department of Oncology, Royal Surrey 
County Hospital, Guildford, UK 
richard.shaffer@nhs.net 
 Denise Sheehan Royal Devon and Exeter Hospital, 
Exeter, UK 
denise.sheehan@nhs.net 
 Matthew Simms Hull & East Yorkshire Hospitals NHS 
Trust, Hull, UK 
Matthew.Simms@hey.nhs.uk 
 Narayanan Srihari Shrewsbury and Telford Hospitals NHS 
Trust, Shrewsbury, UK  
nn_srihari@yahoo.co.uk 
 Räto Strebel Kantonsspital Graubünden, Chur, 
Switzerland;  
Swiss Group for Cancer Clinical 
Research (SAKK), Bern, Switzerland 
Raeto.Strebel@ksgr.ch 
 Santhanam Sundar Department of Oncology, Nottingham, 
University Hospitals NHS trust, 
Nottingham, UK 
Santhanam.Sundar@nuh.nh
s.uk 
 Shaun Tolan Clatterbridge Cancer Centre, Liverpool, 
UK 
Shaun.Tolan@clatterbridgecl
inic.co.uk 
 David Tsang Southend Hospital, Southend-on-Sea, 
UK 
David.Tsang@southend.nhs.
uk 
 Mohini Varughese Musgrove Park Hospital, Taunton and 
Somerset NHS Foundation Trust, UK  
Mohini.Varughese@tst.nhs.u
k 
 John Wagstaff Swansea University College of Medicine, 
Swansea, UK 
John.Wagstaff@wales.nhs.u
k 
 Mahesh KB Parmar1 MRC Clinical Trials Unit at UCL, London, 
UK 
m.parmar@ucl.ac.uk 
 Nicholas D James1 Institute of Cancer and Genomic 
Sciences, University of Birmingham, 
Edgbaston, Birmingham, UK 
n.d.james@bham.ac.uk 
 And the STAMPEDE investigators  
 1 These authors contributed equally  
  
Correspondence: During consideration -- Matthew Sydes 
After publication: Clinical correspondence - Nicholas James; After 
publication: Methodological correspondence - Mahesh Parmar 
  
Research 
support for 
trial: 
Cancer Research UK (CRUK_A12459), Medical Research Council 
(MRC_MC_UU_12023/25); Janssen, Sanofi-Aventis; Astellas, Clovis 
Oncology, Novartis, Pfizer 
 
 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy072/4910513
by Cardiff University user
on 26 March 2018
Treatment options for hormone naïve prostate cancer 
v2.01; 10-Feb-2018 4/49 
Word Count: Section V101 
(by section) 
   
 Abstract 337    
 RIC 260    
 Introduction 227    
 Methods 895    
 Results 436    
 Discussion 1204    
 Total 2762    
  
 (Word counts include headings and reference numbers) 
  
Note: These results were presented at the European Society of Medical 
Oncology conference in Madrid, Spain (08-Sep-2017) 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy072/4910513
by Cardiff University user
on 26 March 2018
Treatment options for hormone naïve prostate cancer 
v2.01; 10-Feb-2018 5/49 
ABSTRACT 
Background 
Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) 
to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage 
platform randomised controlled protocol recruiting patients with high-risk locally advanced 
or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol 
provides the only direct, randomised comparative data of SOC+AAP vs SOC+DocP. 
 
Method 
Recruitment to SOC+DocP and SOC+AAP overlapped Nov-2011─Mar-2013. SOC was 
long-term ADT or, for most non-metastatic cases, ADT for ≥2yrs and RT to the primary 
tumour. Stratified randomisation allocated pts 2:1:2 to SOC; SOC+docetaxel 75mg/m2
 
3-weekly x6 + prednisolone 10mg daily; or SOC+abiraterone acetate 1000mg + prednisolone 
5mg daily. AAP duration depended on stage & intent to give radical RT. The primary outcome 
measure was death from any cause. Analyses used Cox proportional hazards & flexible 
parametric models, adjusted for stratification factors. This was not a formally-powered 
comparison. A hazard ratio (HR)<1 favours SOC+AAP, HR>1 favours SOC+DocP. 
 
Results 
566 consenting patients were contemporaneously randomised: 189 SOC+DocP, 377 
SOC+AAP. The patients, balanced by allocated treatment were: 342 (60%) M1; 429 (76%) 
Gleason 8-10; 449 (79%) WHO performance status 0; median age 66yr & median PSA 
56ng/ml. With median follow-up 4 years, 149 deaths were reported. For overall survival, 
HR=1·16 (95%CI 0·82-1·65); failure-free survival HR=0·51 (95%CI 0·39-0·67); 
progression-free survival HR=0·65 (95%CI 0·48-0·88); metastasis-free survival HR=0·77 
(95%CI 0·57-1·03); prostate cancer-specific survival HR=1·02 (0·70-1·49); and 
symptomatic skeletal events HR=0·83 (95%CI 0·55-1·25). In the safety population, the 
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proportion reporting ≥1 grade 3, 4 or 5 adverse events ever was 36%, 13% and 1% 
SOC+DocP, & 40%, 7% and 1% SOC+AAP; prevalence 11% at 1 and 2yrs on both arms. 
Relapse treatment patterns varied by arm. 
 
Conclusions 
This direct, randomised comparative analysis of two new treatment standards for 
hormone-naïve prostate cancer (HNPC) showed no evidence of a difference in overall or 
prostate cancer-specific survival, nor in other important outcomes such as symptomatic 
skeletal events, suggesting that Worst toxicity grade over entire time on trial was similar but 
comprised different toxicities in line with the known properties of the drugs.  
 
Trial registration 
Clinicaltrials.gov: NCT00268476 
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RESEARCH IN CONTEXT 
Evidence before this study  
Abiraterone acetate plus prednisone/prednisolone (AAP) and docetaxel with 
prednisone/prednisolone (DocP) have separately been shown to improve survival when used 
in addition to the previous international standard-of-care for hormone-sensitive prostate 
cancer of androgen deprivation therapy with further therapy such as AAP or DocP on relapse. 
This has been confirmed in a number of separate trials and on meta-analysis. The largest 
body of evidence for both AAP and DocP comes from the STAMPEDE platform trial.  
 
Added value of this study  
Recruitment to DocP and AAP overlapped in STAMPEDE giving the only head-to-head evidence 
comparing these two new standard treatment approaches. We report data from the 566 
patients who were directly randomised between these two treatment approaches while the 
two research arms were both open to recruitment. The data show strong evidence favouring 
SOC+AAP on earlier, more biochemically driven outcome measures. For longer-term, more 
clinically-driven outcome measures, including bone complications, prostate cancer-specific 
and overall survival, there is no evidence of a significant difference between AAP and DocP. 
  
Implications of all the available evidence  
The reported trials and meta-analyses showed a larger effect on survival for AAP over the 
previous standard-of-care than did DocP over the standard standard-of-care. These data 
show that the story may be more complicated. No other directly randomised data on survival 
of these treatments are available. Individual patient data network meta-analysis using all of 
the published trials are warranted, accounting for differences in patient characteristics, 
treating clinicians and centres and salvage treatment access. The STAMPEDE team is 
collaborating with the STOPCAP meta-analysis group to achieve this. 
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1. INTRODUCTION 
For several decades, the standard-of-care (SOC) for most patients with high-risk locally 
advanced or metastatic prostate cancer has been long-term androgen deprivation therapy 
(ADT) alone. The past few years there have been great changes, first with results from 
randomised controlled trials showing a survival advantage compared to ADT alone for adding 
radiotherapy to the prostate in men with non-metastatic disease and no known nodal 
involvement;1-3 then with systemic treatments for all men starting long-term hormone 
therapy: docetaxel plus prednisolone/prednisone (DocP)4-9 and, most recently, abiraterone 
acetate plus prednisolone/prednisone (AAP).10,11 As both therapeutic combinations are 
effective, there are now two distinct standards-of-care with little information to guide 
clinicians as to which is the more effective; there are no prospective, powered, randomised 
controlled trials that will deliver direct comparative data. 
 
STAMPEDE is a multi-arm, multi-stage platform protocol which assessed both of these 
treatment approaches, separately, against the previous SOC.12,13 The “docetaxel comparison” 
of STAMPEDE recruited patients allocated to SOC+DocP between Oct-2005 and Mar-2013. 
The “abiraterone comparison”, the first comparison to be added to STAMPEDE, recruited 
patients allocated to SOC or SOC+AAP between Nov-2011 and Jan-2014. Each of those 
comparisons had primary outcome measure of overall survival for the patients randomised 
contemporaneously to the control arm and the relevant research arm. Consequently between 
15-Nov-2011 and 31-Mar-2013, patients were directly randomised contemporaneously 
between these two research arms (and other research arms) and we now present these data.  
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2. METHODS 
2.1 Trial design 
The STAMPEDE protocol and design have been described in detail elsewhere.7,10,12,14 Briefly, 
STAMPEDE comprises a series of multi-arm multi-stage comparisons that have overlapped in 
recruitment and follow-up time.  
 
2.2 Patient selection 
Eligible patients were those starting long-term ADT for the first time. This was defined as 
patients with metastatic disease, nodal involvement or node negative, non-metastatic disease 
with two or more of three high-risk features: T-category 3 or 4, Gleason sum score 8-10 or 
PSA>40ng/ml. Patients rapidly relapsing after previous local therapy were also permitted if 
they had PSA>20ng/ml or PSA>4ng/ml with a PSA doubling time <6 months or those who 
developed loco-regional or metastatic spread whilst not on hormone therapy. 
 
As with all STAMPEDE comparisons, the primary outcome measure of the two underpinning 
comparisons (against control) was overall survival. Failure-free survival was an intermediate 
primary outcome measure, defined as time from randomisation to the first of: rising PSA 
(where rising PSA was defined as a confirmed rise to >4ng/ml, and >50% above the lowest 
value in the first 6 months after randomisation); new disease or progression of: distant 
metastases, lymph nodes or local disease; or death from prostate cancer. Progression-free 
survival was defined as time from randomisation to the first of: new disease or progression 
of: distant metastases, lymph nodes or local disease; or death from prostate cancer.15 
Metastatic progression-free survival (MPFS) was defined as time from randomisation to death 
from any cause, new metastases or progression of distant metastases. 
 
All patients provided written informed consent; all versions of the protocol have been 
reviewed by the relevant research ethics committees and the regulatory agencies; the original 
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protocol and all subsequent versions involving the introduction of a new research arm and 
comparison were independently peer-reviewed by Cancer Research UK. 
 
Patients have been allocated across a number of research treatments as depicted in 
Figure_1. Here we focus on those patients randomised between 15-Nov-2011 and 
31-Mar-2013, while both the “docetaxel comparison” and the “abiraterone comparison” were 
open to recruitment, and who were allocated to either SOC+DocP or SOC+AAP. 
 
2.3 Trial treatment, masking and follow-up 
The standard-of-care was long-term hormone therapy with LHRH analogues (with short term 
anti-androgen if relevant) or orchidectomy. Unless contraindicated, radiotherapy to the 
prostate was mandated in all patients with N0M0 disease, encouraged in patient with N+M0 
disease, and permitted in patients with M1 disease until the activation of the “M1|RT 
comparison” in Jan-2013. On the DocP arm, docetaxel (75mg/m2) was given once every three 
weeks for six cycles, with prednisolone/prednisone (10mg) daily. On the AAP arm, 
abiraterone acetate (1000mg) with prednisolone/prednisone (5mg) daily was given until PSA, 
clinical and radiological progression or a change of treatment. AAP duration was capped after 
2 years in M0 patients having radical radiotherapy. Modifications for toxicities were described 
in the protocol and previous papers.7 10 Treatment allocation was not masked for practical 
reasons. Patients were seen 6-weekly at first, dropping to 6-monthly after 2 years. Imaging 
scans after baseline were at the investigator’s discretion. 
 
2.4 Randomisation  
Patients were randomised centrally using minimisation with a random element across a 
number of stratification factors using unequal allocation (previously described).7,10 The 
allocation ratio was initially 2:1 control:research; the “abiraterone comparison” was brought 
in with an equal allocation (1:1) ratio to the control. Therefore the allocation ratio here is 1:2 
for SOC+DocP:SOC+AAP. 
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2.5 Statistical analysis 
The comparison presented here is of SOC+AAP against SOC+DocP because both of these 
arms have demonstrated better overall survival than their contemporaneous controls in the 
population of men starting long-term hormone therapy. The protocol specified that research 
arms which were better than the control arm could be compared, following a closed test 
approach. The maturity of the data used for SOC+AAP matches that recently reported10 in the 
primary results and is updated to the same data freeze timepoint for SOC+DocP so is 
longer-term data than previously reported results for this arm.7 
 
The previously-reported comparisons of SOC+DocP vs SOC and SOC+AAP vs SOC had formal 
sample size calculations; there is no formal sample size calculation for this comparison: it is 
an opportunistic comparison between the contemporaneously-recruited research arm 
patients. Although the recruitment overlap is only 17 months, 566 patients were allocated to 
the two research arms of interest and thus contribute substantial information to inform this 
comparison.  
 
Standard survival analysis methods were used, following the approach for each of these 
underpinning comparisons; hazard ratios (HR) were estimated from adjusted Cox models, 
after checking that the proportional hazards assumption held, where a hazard ratio (HR)<1 
represents evidence in favour of SOC+AAP and HR>1 represents evidence in favour of 
SOC+DocP. Nominal confidence intervals are presented at the 95% level. A p-value <0.1 was 
considered indicative of treatment-baseline characteristic interaction, recognising the limited 
power of the heterogeneity tests. Efficacy analyses were done in the intention-to-treatment 
basis, by allocated treatment. Safety analyses were done only in patients who started their 
allocated treatment. 
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2.6 Role of the funding source 
The trial was sponsored by the UK Medical Research Council (MRC) and conducted by the 
MRC Clinical Trials Unit at UCL. In the United Kingdom the trial was supported by the UK 
Clinical Research Network, and funded by Cancer Research UK and the Medical Research 
Council, and in Switzerland, by the Swiss Group for Cancer Clinical Research (SAKK). Industry 
collaboration and support has been provided to STAMPEDE by Astellas, Clovis Oncology, 
Janssen, Novartis, Pfizer and Sanofi-Genzyme. MRC employees were central to the conduct of 
the trial and the development of this manuscript. Authors MRSy and MRSp accessed raw data. 
The funding bodies had no role in determining this publication. 
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3. RESULTS 
3.1 Accrual and characteristics 
The dataset for this comparison was frozen on 10-Feb-2017. Between 15-Nov-2011 and 
31-Mar-2013, 1,348 patients joined all open arms STAMPEDE. Of the 566 randomised to the 
comparison reported here, 189 (14%) were allocated to SOC+DocP, 377 (28%) to SOC+AAP. 
The flow of patients to this comparison is shown in Figure_2. Table_1 shows the baseline 
characteristics of patients in this comparison which differ only slightly from the previous 
papers (summarised in Supp_Table_1) Median follow-up, calculated by reverse censoring on 
survival, was 48 months.  
 
3.2 Overall survival 
There were 44/189 (23%) deaths on the SOC+DocP arm and 105/377 (28%) deaths on the 
SOC+AAP arm. The estimated HR=1·16 (95%CI 0·82-1·65; p=0·40) (Figure_3A). Estimates 
in patients with and without metastases are shown in Table_2, with HR=1·51 (95%CI 0·58-
3·93) in M0 patients and HR=1·13 (95%CI 0·77-1·66) in M1 patients. There was no evidence 
of interaction in the treatment effect by baseline metastases (p=0·69). 
 
126/149 deaths were attributed to prostate cancer, comprising 10/22 and 116/127 deaths in 
patients with M0 and M1 disease at entry, respectively. Competing risks regression shows no 
evidence of a difference in prostate cancer-specific survival (sub-HR=1·02, 95%CI 0·70—
1·49). For non-prostate cancer-specific survival, with 23/149 deaths attributed to other 
causes, the sub-HR was 2·33 (95%CI 0·78-6·99). There was no evidence of heterogeneity of 
treatment effect by baseline metastases in either outcome. 
 
3.3 Other efficacy outcome measures 
Table_2 shows the effect size overall and by whether the patients had metastases at entry 
for failure-free survival, progression-free survival, metastatic progression-free survival and 
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skeletal related events. There is no evidence of heterogeneity of the treatment effect by 
baseline metastases in any of these outcome measures. Figure_4 summarises the effect for 
all outcome measures. 
 
3.4 Safety 
The safety population includes people who started their allocated treatment. While nearly all 
patients allocated to AAP started it, a proportion of those patients allocated to receive 
docetaxel declined to start it. Table_3 summarises the worst toxicity reported for patients 
over their time on trial in the safety population and shows differing patterns for adverse 
events according to treatment. The prevalence of grade 3 or 4 toxicity in patients with 
assessments at 1 year without a prior FFS event was 11% SOC+DocP and 11% SOC+AAP; at 
2 years this was 11% SOC+DocP and 11% SOC+AAP. 
 
3.5 Second-line treatment  
Figure_5 shows time from randomisation to any subsequent exposure to docetaxel or AR-
targeted therapy with AAP or enzalutamide. Figure_6 shows time from an FFS event to 
reported exposure to selected treatments that are licensed for CRPC: docetaxel, AAP, 
enzalutamide. There was limited reported use of cabazitaxel, radium and sipuleucel-T at this 
point (not shown).  
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4. DISCUSSION 
We and others have previously shown a survival advantage for adding docetaxel (with or 
without prednisolone/prednisone) and for adding abiraterone acetate and 
prednisolone/prednisone, in patients starting long-term hormone therapy for the first time.4-11 
However, there is currently no direct evidence available to help clinicians or patients assess 
which combination might be better. Here, we reported a pre-specified (but not pre-powered) 
analysis using only patients who were randomised during a period of the study when 
recruitment to the two research arms overlapped. We used data collected prospectively from 
over 100 sites across two countries as part of a clinical trial protocol. The MAMS platform 
design of STAMPEDE, an approach sometimes referred to as a master protocol,16 facilitated 
this comparison. Separate, traditional, two-arm RCTs, would not have allowed any directly-
randomised comparative evidence to be available so soon. 
 
Our recently-reported overall treatment effect on survival, in STAMPEDE, for adding AAP 
compared to the standard-of-care (HR=0·63)10 was larger than the previously-reported 
overall treatment effect, in STAMPEDE, on survival for adding DocP to the same 
standard-of-care (HR=0·78).7 The earlier secondary efficacy outcome measures favoured 
adding AAP over DocP, including failure-free survival -- perhaps unsurprising given the direct 
anti-androgenic action of AAP (around four in every five FFS events was driven only by a rise 
in PSA) and progression-free survival (which excludes rising PSA). There was weak evidence 
favouring AAP for metastatic progression-free survival and no evidence of a difference in 
symptomatic skeletal events, prostate cancer-specific survival or overall survival.  
 
Comparing the results indirectly of these two therapies by readers extracting data from 
STAMPEDE’s AAP and docetaxel papers7,10 may not be the most appropriate way to compare 
the relative effectiveness: the patient cohorts were all not randomised contemporaneously 
and there may be confounding biases when comparing the two datasets, in particular, many 
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DocP patients had very limited salvage CRPC options compared to AAP patients, simply due to 
the timing of licences of new therapies (see below).  
 
Importantly, the two therapies are being used in different ways. AAP is used until the patient 
has castrate-resistant prostate cancer (CRPC), often lasting many years and consequently 
exhausting a major therapy option for CRPC. In contrast, DocP is given as an 18 week course 
thus all CRPC options should remain available. Our data reveal important differences in the 
pattern of treatment failure yet we do not see any differences in survival, suggesting that the 
relative time spent before and after first-line treatment failure are quite different by initial 
treatment. This may explain why the early, often biochemically-driven outcome measures, 
favour AAP but the later post CRPC endpoints such as skeletal events, prostate cancer-
specific survival and overall survival show no good evidence of a difference. Men receiving 
DocP will thus spend longer with CRPC than men receiving AAP but with a broader range of 
more effective options available. Supp_Figure_1 shows the status of all patients at each 
moment in time after randomisation. That the DocP cohort had more durable survival after 
failure, perhaps longer than before failure, may be important in counselling patients 
biochemically failing after DocP.  
 
The number of events is an important consideration in time-to-event analyses. The number of 
patients with metastases at baseline was balanced by arm, but, particularly because of their 
poorer prognosis, these patients tend to predominate in this analysis. There is no evidence of 
heterogeneity in the treatment effect by baseline metastasis for any of the outcome 
measures, but power to detect any heterogeneity is very limited, especially in later outcome 
measures with fewer events. 
 
The patterns of toxicity are quite different for the two treatment approaches, consistent with 
the known effects of the drugs. The proportion of patients reporting at least one grade 3 or 
worse toxicity was similar and in line with previously reported toxicities for these agents 
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(Table_3). In patients who started their allocated treatment and who are without disease 
progression at 1 year, the prevalence of grade 3 or worse toxicity was about 11% on both 
arms and very similar to our previous estimate for SOC. Nearly all patients started their 
allocated abiraterone, whereas about one in twelve patients did not start their allocated 
docetaxel. Our results may change future compliance with both treatments in routine 
practice; but the lack of compliance with allocated treatment for docetaxel is likely to have 
had some impact on our estimated effect sizes. 
 
A key limitation is that the comparison was opportunistic and not designed in the usual way, 
hence power is limited to detect any realistic differences. The trigger for the analysis was the 
reporting of our “abiraterone comparison” data.10 The unequal allocation ratio reflects the 
planned design of the comparisons. The allocated treatment being given was not masked for 
practical reasons. This, of course, allowed for relapse therapies to be given at the 
investigator’s discretion. We observed that after relapse, many patients received the 
treatment class that they had not received up-front.  
 
Salvage options have changed over time: men recruited earlier on to DocP (2005-2013) will 
have had very different options to those recruited later to AAP (2011-2014) when there were 
more CRPC therapies likely available, including AAP,17,18 cabazitaxel,19 docetaxel,20,21 
enzalutamide,22,23 radium-22324 and sipuleucel-T25 (although not widely accessible in Europe). 
For this analysis, we limited ourselves to patients contemporaneously randomised to either 
arm to make this comparison as fair as possible. However, failure-free survival events 
generally happened sooner with DocP than with AAP in time from randomisation and, 
therefore, calendar year (Table_4) may partially influence outcomes. Furthermore, a FFS 
event was more of an indication to change treatments on DocP; AAP continued beyond this 
point.  
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As far as we are aware there are no ongoing randomised trials directly comparing adding AAP 
vs adding docetaxel for patients starting long-term ADT. All of our published STAMPEDE data 
have contributed to the STOpCaP aggregate data network meta-analysis which has used all of 
the reported randomised controlled trials in metastatic patients to perform indirect 
comparisons and allow some assessment of potential ranking of effective therapies. This 
aggregate data analysis (co-submitted) will be supplemented by a forthcoming individual 
patient data (IPD) network meta-analysis which will hopefully provide a more accurate 
reflection of the temporal interval between the application of the two different therapies, to 
which STAMPEDE will contribute all relevant data. We will continue to follow-up patients for 
long-term outcome measures. 
 
Considering their mechanisms of action and their proven oncological benefits, the question is 
raised of whether a combination of AAP plus docetaxel might lead to an approximately 
additive benefit of using them both, further extending survival. Randomised data on 
docetaxel with or without abiraterone will emerge from a subset the PEACE-1 triala, as will 
non-randomised, time-stratified data on abiraterone with or without docetaxel. Similarly 
comparative data will also emerge for enzalutamide, another AR-targeted therapy, from the 
ENZAMET trialb and with the combination of enzalutamide and AAP in STAMPEDE (Figure 1).  
 
                                           
a https://clinicaltrials.gov/ct2/show/NCT01957436 
b https://clinicaltrials.gov/ct2/show/NCT02446405 
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In conclusion, there are now two systemic therapies, DocP and AAP, which have shown a 
survival benefit from randomised controlled trials when added to treatment for patients 
starting long-term androgen deprivation therapy for the first time. The evidence from our 
directly randomised data comparing these two therapies showed no evidence of a difference 
in overall or prostate cancer-specific survival, nor in other important outcomes such as 
symptomatic skeletal events, suggesting that both currently remain viable new standards-of-
care. 
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ABBREVIATION LIST 
Abbreviation Expansion 
AAP Abiraterone acetate and prednisolone (UK) / prednisolone (Switzerland) 
ADT Androgen deprivation therapy 
CRPC Castrate-resistant prostate cancer 
CRUK Cancer Research UK 
CTA Clinical Trials Authorisation 
CTU MRC Clinical Trials Unit 
DocP Docetaxel and prednisolone 
FFS Failure-free survival 
HNPC Hormone-naïve prostate cancer 
HR Hazard ratio 
IDMC Independent Data Monitoring Committee 
IQR Interquartile range 
MAMS Multi-arm Multi-stage 
MRC Medical Research Council 
MPFS Metastatic progression-free survival 
MRC Medical Research Council 
OM Outcome measure 
OS Overall survival 
PFS Progression-free survival 
PIS Patient Information Sheet 
RCT Randomised Controlled Trial 
SOC Standard-of-care 
STAMPEDE Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of 
Drug Efficacy 
TMG Trial Management Group 
TSC Trial Steering Committee 
UCL University College London 
WHO PS WHO performance Status 
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TABLES AND FIGURES 
Figure 1: Activity-by-time diagram: patients included in this comparison 
 
Key 
SOC = Standard-of-care 
Doc = Docetaxel 
Abi = Abiraterone acetate + prednisone/prednisolone 
 
Note 
Boxes represents periods of recruitment (x-axis) to each of the trial arms (y-axis). The yellow-bars 
represent recruitment periods contributing to this analysis; the grey boxes other recruitment period, 
past and future, contributing to other aspects of the STAMPEDE. The squares represent the time point of 
the first key comparative analyses for each comparison in black and for this comparison in yellow. 
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Figure 2: CONSORT diagram 
 
Key 
SOC  = Standard-of-care 
DocP  = Docetaxel + prednisolone/prednisone 
AAP  = Abiraterone acetate + prednisolone/prednisone 
 
Note 
Selection of patients for this comparison 
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Figure 3: Efficacy analysis – survival, metastases-free survival, failure-free survival, skeletal-related events 546 
(a) Overall survival (b) Metastases-free survival 
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(c) Failure-free survival (d) Symptomatic skeletal events 
  
 547 
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(e) Metastatic progression-free survival  
 
 
Note 
Kaplan-Meier (“survival”) plots for the key efficacy outcome measures. Each step down the y-axis represents an event. The number of patients 
contributing information (“at risk”) over time since randomisation are shown under the table. The number of patients with an event between these 
points is shown in brackets. The number of patients censored in a time window is not shown, but is calculable as the difference between the number of 
patients at risk at two times points and the number of patients with events e.g. on Figure 3e between 0 and 6 months on the SOC+AAP arm (377-
362)-12=3 patients are censored. 
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Figure 4: Depiction of disease state over time 548 
 
  549 
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Figure 5: Time from randomisation to reported starting docetaxel, AAP, enzalutamide or AR-targeting therapy 550 
(a) Time from randomisation to docetaxel (b) Time from randomisation to any AR-targeted therapy 
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(c) Time from randomisation to AAP  (d) Time from randomisation to enzalutamide 
  
Note 
Kaplan-Meier (“survival”) plots showing cumulative incidence of exposure to treatments after randomisation. Each step up the y-axis 
represents an event, namely starting that particular treatment. The number of patients contributing information (“at risk”) over time since 
randomisation are shown under the table. The number of patients with an event between these points is shown in brackets. For example, on 
Figure 4c between 24 and 36 months after randomisation, 4 patients on the SOC+DocP arm report starting abiraterone and (150-129)-4 are 
17 are censored and may start in the future. 
 551 
  552 
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Figure 6: Time from failure-free survival event to subsequent treatment by allocated treatment 553 
(a) SOC+DocP allocated group (b) SOC+AAP allocated group 
  
Note 
Kaplan-Meier (“survival”) plots showing cumulative incidence of exposure to treatments after a failure-free survival (FFS) event. Each step up 
the y-axis represents an event, namely starting that particular treatment.  
 554 
 555 
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Table 1:  Baseline characteristics of patients allocated to SOC+DocP or SOC+AAP 
by whether contributing to the direct comparison 
 SOC+DocP SOC+AAP Overall 
Characteristic     N % 
       
Metastases       
M0 74 39 150 40 224 40 
M1 115 61 227 60 342 60 
       
Nodal stage       
N0 82 43 158 42 240 44 
N+ 99 52 202 53 301 56 
NX 8 4 17 5 25 n/a 
       
Combination       
N0 M0 43 23 84 22 127 22 
N+M0 31 16 66 18 97 17 
N0 M1 39 21 74 20 113 20 
N+ M1 68 36 136 36 204 36 
NX M1 8 4 17 5 25 4 
       
Tumour category       
<T3 24 13 36 10 60 11 
T3 123 65 249 66 372 69 
T4 39 20 68 18 107 20 
Tx 3 2 24 6 27 n/a 
       
Gleason category       
<=7 35 19 91 25 126 23 
8 to 10 153 81 276 75 429 76 
Unknown 1 --- 10 --- 11 n/a 
       
Previous local therapy       
No 183 97 350 93 533 94 
Yes 6 3 27 7 33 6 
       
WHO performance status       
0 149 79 300 80 449 79 
1 to 2 40 21 77 20 117 21 
       
Age (years)       
<70 134 71 267 71 401 71 
70+ 55 29 110 29 165 29 
Median (quartiles) 66 (62-71) 66 (61-70) 66 (62-70) 
Mean (sd) 66 (7) 66 (7) 66 (7) 
       
Use of NSAID or aspirin       
No use 141 75 280 74 421 74 
Uses either 48 25 97 26 145 26 
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 SOC+DocP SOC+AAP Overall 
Characteristic     N % 
PSA (ng/ml)       
Median (quartiles) 58 (29-162) 55 (20-194) 56 (22-185) 
Mean (sd) 193 (421) 274 (631) 247 (571) 
        
Ln PSA (ng/ml)       
Median (quartiles) 4.1 (3.4-5.1) 4.0 (3.0-5.3) 4.0 (3.1-5.2) 
Mean (sd) 4.2 (1.4) 4.2 (1.6) 4.2 (1.5) 
        
RT planned       
M0, yes   57 77 118 79 175 78 
M0, no 17 23 32 21 49 22 
       
M1, yes 12 10 21 9 33 10 
M1, no 103 89 206 91 309 90 
       
Hypertension       
Yes (still fit for trial) 64 34 149 40 213 38 
No 125 66 227 60 352 62 
       
Year of randomisation       
2011 15 8 27 7 42 7 
2012 138 73 277 73 415 73 
2013 36 19 73 19 109 19 
       
 
 
 
 
.   
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Table 2: Hazard ratio for SOC+AAP relative to SOC+DocP from adjusted Cox models 
Outcome 
measure 
Patient 
group 
Events/Pts 
SOC+DocP 
Events/Pts 
SOC+AAP 
Hazard ratio3 
(95% CI) p-value 
Interaction 
by 
metastases 
p-value 
Failure-free survival1 
 All 97/189 122/377 0·51 (0·39 to 0·67) <0·001  
       
 M0 18/74 13/150 0·34 (0·16 to 0·69) 0·003  
 M1 79/115 109/227 0·56 (0·42 to 0·75) <0·001 0·169 
       
Progression-free survival1 
 All 72/189 103/377 0·65 (0·48 to 0·88) 0·005  
       
 M0 10/74 9/150 0·42 (0·17 to 1·05) 0·064  
 M1 62/115 94/227 0·69 (0·50 to 0·95) 0·023 0·323 
       
Metastatic progression-free survival2 
 All 71/189 118/377 0·77 (0·57 to 1·03) 0·079  
       
 M0 10/74 18/150 0·91 (0·42 to 2·01) 0·824  
 M1 61/115 100/227 0·76 (0·55 to 1·04) 0·085 0·744 
       
Freedom from symptomatic skeletal events 
 All 36/189 63/377 0·83 (0·55 to 1·25) 0·375  
       
 M0 2/74 5/150 1·28 (0·24 to 6·67) 0·771  
 M1 34/115 58/227 0·82 (0·53 to 1·25) 0·351 0·648 
       
Overall survival 
 All 44/189 105/377 1·16 (0·82 to 1·65) 0·404  
       
 M0 6/74 16/150 1·51 (0·58 to 3·93) 0·395  
 M1 38/115 89/227 1·13 (0·77 to 1·66) 0·528 0·691 
       
Outcome 
measure 
Patient 
group 
Events/Pts 
SOC+Doc 
Events/Pts 
SOC+AAP 
Sub-hazard 
ratio4 (95% CI) p-value 
Interaction 
by 
metastases 
p-value 
Death from prostate cancer5 
 All 40/189 86/377 1·02 (0·70 to 1·49) 0·916  
       
 M0 4/74 6/150 0·82 (0·24 to 2·81) 0·751  
 M1 36/115 80/227 1·05 (0·71 to 1·56) 0·807 0·620 
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Death from other causes6 
 All 4/189 19/377 2·33 (0·77 to 6·99) 0·131  
       
 M0 2/74 10/150 3·00 (0·66 to 13·66) 0·155  
 M1 2/115 9/227 1·91 (0·43 to 8·41) 0·393 0·771 
       
1 Includes death from prostate cancer 
2 Includes death from any cause 
3 From Cox proportional hazards model, adjusted for stratification factors at randomisation 
(except hospital and choice of hormone therapy) and stratified by time period 
4 From competing risks regression model, adjusted for stratification factors at randomisation 
(except hospital and choice of hormone therapy) and time period, and treating causes of 
death other than the focus as a competing event 
5 Cause attributed on central death review; prostate cancer death as event, other cause of 
death as competing event 
 
6 Cause attributed on central death review; other causes of death as event, prostate cancer 
as competing event   
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Table 3: Worst adverse event (grade) reported over entire time on trial 
 
 SOC+Doc 
(n=189) 
SOC+AAP 
(n=377) 
Safety population   
Number of patients included in analysis* 172 373 
Patients with an adverse event – no. (%)   
Grade 1-5 adverse event 172 (100) 370 (99) 
Grade 3-5 adverse event 86 (50) 180 (48) 
Grade 3-5 adverse events – no. (%)   
 Endocrine disorder 15 (9) 49 (13) 
 Febrile neutropenia 29 (17) 3 (1) 
 Neutropenia (neutrophils) 22 (13) 4 (1) 
 General disorder  18 (10) 21 (6) 
 Fatigue 7 (4) 8 (2) 
 Oedema 1 (1) 2 (1) 
 Musculoskeletal disorder 9 (5) 33 (9) 
 Cardiovascular disorder 6 (3) 32 (9) 
 Hypertension 0 (0) 12 (3) 
 Myocardial Infarction 2 (1) 4 (1) 
 Cardiac dysrhythmia 1 (1) 5 (1) 
 Gastrointestinal disorder 9 (5) 28 (8) 
 Hepatic disorder 1 (1) 32 (9) 
 Increased AST 0 (0) 6 (2) 
 Increased ALT 1 (1) 23 (6) 
 Respiratory disorder 12 (7) 11 (3) 
 Dyspnoea 4 (2) 1 (1) 
 Renal disorder 5 (3) 20 (5) 
 Lab abnormalities 9 (5) 11 (3) 
 Hypokalaemia 0 (0) 3 (1) 
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Table 4: Year of FFS event and death by arm 
 
 FFS event  Death 
 SOC+DocP SOC+AAP  SOC+DocP SOC+AAP 
Year of 
event 
N % N %  N % N % 
2012 14 7% 25 6%  1 1% 5 1% 
2013 38 20% 43 11%  12 6% 18 5% 
2014 25 13% 33 9%  9 5% 33 9% 
2015 14 7% 11 3%  16 8% 38 10% 
2016 6 3% 10 3%  6 3% 11 3% 
No event 92 49% 255 68%  145 77% 272 72% 
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